Get the StoQuant digest — free
Free StoQuant digest by email. No account needed.
See today's research picks.
LCTX vs NAUT — Stock Comparison
Compare LCTX and NAUT side-by-side on StoQuant: LCTX Q-Score 25 vs NAUT 60; analyst signal 75 vs 56. Plus alt data signals, insider buying, catalysts, strategic edges, short interest, social sentiment, and macro context.
Side-by-side snapshot
- LCTX — Lineage Cell Therapeutics, Inc. · Health Care · market cap $253M · Q-Score verdict Strong Sell (25.0, grade F) · analyst signal 75/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: competitive moat 92/100, analyst consensus 73/100 · weakest signals: technicals 7/100. Full LCTX research.
- NAUT — Nautilus Biotechnology, Inc. · Health Care · market cap $412M · Q-Score verdict Buy (60.0, grade B) · analyst signal 56/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: earnings quality 64/100, analyst consensus 56/100 · weakest signals: competitive moat 15/100, technicals 0/100. Full NAUT research.
What you can compare
- Q-Score: StoQuant's composite 0–100 rating based on 140+ financial signals.
- Alt data signals: Google Trends, EDGAR 8-K filings, job postings, and more.
- Insider activity: Cluster scores and recent Form 4 buying.
- Catalysts: Earnings, analyst changes, M&A, clinical trials, and SEC events.
- Strategic edges: Competitive moat and durable advantage analysis.
- Short interest & social sentiment: Short % float, social mention volume, and bullish/bearish breakdown.
- Macro context: Market regime and sector rotation alignment.
Deep dive: LCTX research · NAUT research. Sign in to StoQuant to run live comparisons for any tickers. Sign up free →
Register founding interest — Pro $29/mo or Power $79/mo
Paid plans aren’t for sale yet. Leave your email to lock founding pricing (Pro $29, Power $79); we’ll reach out personally.